Vaccination against herpes zoster and postherpetic neuralgia in France: A cost-effectiveness analysis

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 13, Issue 3, 2013, Pages 393-406

  Bresse, Xavier ^a   Annemans, Lieven ^b   Préaud, Emmanuelle ^a   Bloch, Karine ^a   Duru, Gérard ^c   Gauthier, Aline ^d  

^a SANOFI PASTEUR   (France)

^b GHENT UNIVERSITY   (Belgium)

^c CYKLAD GROUP   (France)

^d Amaris   (United Kingdom)

Author keywords

Vaccination

Indexed keywords

HERPES SIMPLEX VACCINE;

AGED; COHORT ANALYSIS; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE ASSOCIATION; DRUG COST; EUROQOL FIVE DIMENSION QUESTIONNAIRE; EVIDENCE BASED MEDICINE; FEMALE; FRANCE; HEALTH INSURANCE; HERPES SIMPLEX; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTHERPETIC NEURALGIA; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; STATISTICAL MODEL; VACCINATION;

AGE FACTORS; AGED; COST-BENEFIT ANALYSIS; FRANCE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MARKOV CHAINS; NEURALGIA, POSTHERPETIC; QUALITY OF LIFE; QUESTIONNAIRES; VACCINATION;

EID: 84885134416     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.13.19     Document Type: Review

References (52)

1. Johnson RW, Bouhassira D, Kassianos G, Leplege A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med 8, 37 (2010)
2. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J. Pain 6(6), 356-363 (2005)
3. Bouhassira D, Chassany O, Gaillat J et al. Patient perspective on herpes zoster and its complications: an observational prospective study in patients aged over years in general practice. Pain 153(2), 342-349 (2012)
4. Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin. Proc. 84(3), 274-280 (2009)
5. Bowsher D. The lifetime occurrence of herpes zoster and prevalence of postherpetic neuralgia: a retrospective survey in an elderly population. Eur. J. Pain 3(4), 335-342 (1999)
6. Oxman MN, Levin MJ, Johnson GR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352(22), 2271-2284 (2005). • Publication of the pivotal Phase III study of herpes zoster vaccination that is the basis used for many model parameters
7. Yawn BP, Saddier P, Wollan PC et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin. Proc. 82(11), 1341-1349 (2007)
8. Hope-Simpson RE. Postherpetic neuralgia. J. R. Coll. Gen. Pract. 25(157), 571-575 (1975)
9. Sengupta N, Booy R, Schmitt HJ et al. Varicella vaccination in Europe: are we ready for a universal childhood programme? Eur. J. Pediatr. 167(1), 47-55 (2008)
10. Nardone A, De Ory F, Carton M et al. The comparative sero-epidemiology of varicella zoster virus in countries in the European region. Vaccine 25(45), 7866-7872 (2007)
11. Khoshnood B, Debruyne M, Lancon F et al. Seroprevalence of varicella in the French population. Pediatr. Infect. Dis. J. 25(1), 41-44 (2006)
12. Johnson R, Mcelhaney J, Pedalino B, Levin M. Prevention of herpes zoster and its painful and debilitating complications. Int. J. Infect. Dis. 11(Suppl. 2), S43-S48 (2007)
13. Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. Br. Med. J. 321(7264), 794-796 (2000)
14. Van Wijck AJ, Opstelten W, Moons KG et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet 367(9506), 219-224 (2006)
15. Schmader KE, Gnann JW Jr, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J. Infect. Dis. 197(Suppl. 2), S207-S215 (2008)
16. Czernichow S, Dupuy A, Flahault A, Chosidow O. Herpes zoster: incidence study among 'sentinel' general practitioners. Ann. Dermatol. Venereol. 128(4), 497-501 (2001)
17. Dworkin RH, Carrington D, Cunningham A et al. Assessment of pain in herpes zoster: lessons learned from antiviral trials. Antiviral Res. 33(2), 73-85 (1997)
18. Mick G, Gallais JL, Simon F et al. Burden of herpes zoster and postherpetic neuralgia: incidence, proportion, and associated costs in the French population aged or over. Rev. Epidemiol. Santé Publique 58(6), 393-401 (2010). • French study of herpes zoster epidemiological and economic burden
19. Gauthier A, Breuer J, Carrington D, Martin M, Remy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol. Infect. 137(1), 38-47 (2009)
20. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin. J. Pain 18(6), 350-354 (2002)
21. Opstelten W, Mauritz JW, De Wit NJ, VanWijck AJ, Stalman WA, Van Essen GA. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam. Pract. 19(5), 471-475 (2002)
22. Thyregod HG, Rowbotham MC, Peters M, Possehn J, Berro M, Petersen KL. Natural history of pain following herpes zoster. Pain 128(1-2), 148-156 (2007)
23. Stankus SJ, Dlugopolski M, Packer D. Management of herpes zoster (shingles) and postherpetic neuralgia. Am. Fam. Physician 61(8), 2437-2444; 2447-2438 (2000)
24. Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of herpes zoster: a prospective population based study. Vaccine 24(9), 1308-1314 (2006)
25. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch. Intern. Med. 155(15), 1605-1609 (1995)
26. Bruxelle J, Pinchinat S. Effectiveness of antiviral treatment on acute phase of herpes zoster and development of post herpetic neuralgia: review of international publications. Med. Mal. Infect. 42(2), 53-58 (2012)
27. Li Q, Chen N, Yang J et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst. Rev. 2, CD006866 (2009)
28. Schmader KE, Levin MJ, Gnann JW Jr et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin. Infect. Dis. 54(7), 922-928 (2012)
29. Schmader KE, Oxman MN, Levin MJ; the Shingles Prevention Study Group. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin. Infect. Dis. 55(10), 1320-1328 (2012). • Publication of herpes zoster vaccine long-term follow-up data
30. Moore L, Remy V, Martin M, Beillat M, Mcguire A. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff. Resour. Alloc. 8, 7 (2010). • First publication of herpes zoster vaccination cost-effectiveness using the same model to in this article
31. Annemans L, Bresse X, Gobbo C, Papageorgiou M. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J. Med. Econ. 13(3), 537-551 (2010)
32. Szucs TD, Kressig RW, Papageorgiou M et al. Economic evaluation of a vaccine for the prevention of herpes zoster and postherpetic neuralgia in older adults in Switzerland. Hum. Vaccin. 7(7), 749-756 (2011)
33. Weinstein MC, O'Brien B, Hornberger J et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health 6(1), 9-17 (2003)
34. Cartwright WS. Methods for the economic evaluation of health care programmes, second edition. By Michael F. Drummond, Bernie O'Brien, Greg L. Stoddart, George W Torrance. Oxford: Oxford University Press, 1997. J. Ment. Health Policy Econ. 2(1), 43 (1999)
35. Gonzalez Chiappe S, Sarazin M, Turbelin C et al. Herpes zoster: burden of disease in France. Vaccine 28(50), 7933-7938 (2010)
36. Bala MV, Wood LL, Zarkin GA, Norton EC, Gafni A, O'Brien B. Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. J. Clin. Epidemiol. 51(8), 667-676 (1998)
37. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 25(49), 8326-8337 (2007). • First cost-effectiveness publication of herpes zoster vaccination
38. Tuppin P, Choukroun S, Samson S, Weill A, Ricordeau P, Allemand H. Vaccination against seasonal influenza in France in 2010 and 2011: decrease of coverage rates and associated factors. Presse Med. 41(11), e568-e576 (2012)
39. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results from a cross-sectional survey. Eur. J. Pain 10(2), 127-135 (2006)
40. Oxman MN, Levin MJ. Vaccination against herpes zoster and postherpetic neuralgia. J. Infect. Dis. 197(Suppl. 2), S228-S236 (2008)
41. Van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 27(9), 1454-1467 (2009). • Publication from the UK Health Protection Agency of herpes zoster vaccination cost-effectiveness that has been used to assess the external validity of this model in the absence of an alternative French published model
42. Van Lier A, Van Hoek AJ, Opstelten W, Boot HJ, De Melker HE. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in The Netherlands. BMC Health Serv. Res. 10, 237 (2010)
43. Szucs TD, Pfeil AM. A systematic review of the cost effectiveness of herpes zoster vaccination. Pharmacoeconomics 31(2), 125-136 (2013)
44. Goeree R, O'Brien BJ, Blackhouse G. Principles of good modeling practice in healthcare cost-effectiveness studies. Expert Rev. Pharmacoecon. Outcomes Res. 4(2), 189-198 (2004)
45. Najafzadeh M, Marra CA, Galanis E, Patrick DM. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics 27(12), 991-1004 (2009)
46. Brisson M, Pelissier JM, Camden S, Quach C, De Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum. Vaccin. 4(3), 238-245 (2008)
47. Pelissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 25(49), 8326-8337 (2007)
48. Berrut G BX, Bloch K, Fernandes J, Vainchtock A. Ophthalmic zoster in France: burden and severity in the hospital setting. Presented at: The World Ophthalmology Congress. Berlin, Germany, 5-9 June 2010
49. Lydick E, Epstein RS, Himmelberger D, White CJ. Herpes zoster and quality of life: a self-limited disease with severe impact. Neurology 45(Suppl. 8), S52-S53 (1995)
50. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on healthrelated quality of life. Clin. Infect. Dis. 39(3), 342-348 (2004)
51. Pickering G, Leplege A. Herpes zoster pain, postherpetic neuralgia, and quality of life in the elderly. Pain Pract. 11(4), 397-402 (2011)
52. Greek Ministry of Health. 2012 National Immunisation Plan for Adults. T1/G.P n°140958. Greek Ministry of Health, Athens, Greece (2011)